FOLFOX

Celyad Oncology Announces Voluntary Pause of CYAD-101-002 Phase 1b Trial

Retrieved on: 
Monday, February 28, 2022
MSD, Molecule, GLOBE, FOLFOX, SA, Patient safety, U.S. Securities and Exchange Commission, Merck & Co., Annual report, CAR, Toxic shock syndrome, Company, Private Securities Litigation Reform Act, Mont-Saint-Guibert, NKG2D, Lymphatic system, Pembrolizumab, Cancer, TIM, Forward-looking statement, Patient, Euronext, Merck, Wallonia, SEC, Pharmaceutical industry

The CYAD-101-002 trial is part of a collaboration with MSD, a tradename of Merck & Co., Inc., Kenilworth, NJ, USA, through a subsidiary.

Key Points: 
  • The CYAD-101-002 trial is part of a collaboration with MSD, a tradename of Merck & Co., Inc., Kenilworth, NJ, USA, through a subsidiary.
  • Our primary commitment is to maintain patient safety, which is why we decided to place the trial on hold while we investigate these events, said Filippo Petti, Chief Executive Officer of Celyad Oncology.
  • Celyad Oncology SA is a clinical-stage biotechnology company focused on the discovery and development of chimeric antigen receptor T cell (CAR T) therapies for cancer.
  • Celyad Oncology was founded in 2007 and is based in Mont-Saint-Guibert, Belgium and New York, NY.

ITM Announces First Patient Treated in Second Phase III Trial, COMPOSE, with ITM-11 (n.c.a. 177Lu-edotreotide) for Treatment of Neuroendocrine Tumors

Retrieved on: 
Tuesday, January 25, 2022
Research, Medical Devices, Clinical Trials, Biotechnology, Radiology, Health, Pharmaceutical, Other Science, Science, Supervisory board, Survival, Overalls, Therapy, FOLFOX, Nuclear medicine, ITM, Radiation, Quality of life, Patient, GEP-NET, B cell, Somatostatin, Gastrointestinal tract, Radionuclide, Radiopharmaceutical, IBAN, Board of directors, Commercial, Gastrointestinal cancer, Cancer, Neoplasm, Everolimus, Hospice, Pancreas, BIC, CEO, Solution, Garching (Munich U-Bahn), HIV disease progression rates, III, Progression-free survival, VAT, Safety, CFO, Leadership, Pharmaceutical industry, Medical imaging, Targeted Radionuclide Therapy, ITM-11 (n.c.a. 177Lu-edotreotide), ITM Isotope Technologies Munich SE, TARGETED RADIONUCLIDE THERAPY, ITM-11 (N.C.A. 177LU-EDOTREOTIDE), ITM ISOTOPE TECHNOLOGIES MUNICH SE

177Lu-edotreotide), for the treatment of gastroenteropancreatic neuroendocrine tumors (GEP-NETs).

Key Points: 
  • 177Lu-edotreotide), for the treatment of gastroenteropancreatic neuroendocrine tumors (GEP-NETs).
  • GEP-NETs are rare types of tumors that can occur in the pancreas or in other parts of the gastrointestinal tract.
  • Due to their frequent asymptomatic and progressive nature, GEPNETs often present late with advanced disease requiring innovative therapeutic measures.
  • The trial design of COMPOSE was recently presented at the 2022 ASCO Gastrointestinal Cancers Symposium ( ASCO-GI ) and the 2021 North American Neuroendocrine Tumor Society ( NANETS ) annual symposium.

ITM Presents Study Design of COMPOSE Phase III Trial with ITM-11 (n.c.a. 177Lu-edotreotide) for Treatment of Neuroendocrine Tumors at ASCO-GI

Retrieved on: 
Wednesday, January 19, 2022
Health, Clinical Trials, Research, Pharmaceutical, Science, Biotechnology, Patient, ITM, Clinical professor, B cell, Mayo Clinic, Commercial, Everolimus, Board of directors, Pancreas, Population, Safety, Garching (Munich U-Bahn), HIV disease progression rates, CEO, Radiation, Leadership, Progression-free survival, VAT, IBAN, Supervisory board, PFS, Progress, Radiopharmaceutical, CFO, MD, Therapy, Radionuclide, Cancer, Neoplasm, Nuclear medicine, FOLFOX, BIC, III, Pharmaceutical industry, Medical imaging, Targeted Radionuclide Therapy, ITM-11 (n.c.a. 177Lu-edotreotide), ITM Isotope Technologies Munich SE, TARGETED RADIONUCLIDE THERAPY, ITM-11 (N.C.A. 177LU-EDOTREOTIDE), ITM ISOTOPE TECHNOLOGIES MUNICH SE

177Lu-edotreotide), compared to best standard of care in patients with welldifferentiated high grade 2 and grade 3 somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors (G2+G3 SSTR+ GEP-NETs).

Key Points: 
  • 177Lu-edotreotide), compared to best standard of care in patients with welldifferentiated high grade 2 and grade 3 somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors (G2+G3 SSTR+ GEP-NETs).
  • COMPOSE is ITMs second phase III trial with ITM-11 following and building upon COMPETE ( NCT03049189 ), in patients with grade 1 and grade 2 GEP-NETs.
  • The primary endpoint of the study is progression-free survival (PFS), which will be assessed every 12 weeks from randomization onwards.
  • As such, I look forward to investigating its potential for patients with advanced GEP-NETs as we move ITM-11 through this Phase III trial.

Global Metastatic Colorectal Cancer Market to 2030 - Insight, Epidemiology and Forecasts - ResearchAndMarkets.com

Retrieved on: 
Monday, January 17, 2022
General Health, Health, Oncology, CAGR, Trastuzumab, Patient, Abdomen, News, Encorafenib, Man, Mortality, Colorectal cancer, Panitumumab, Liver, Clinical trial, Incidence, Cetuximab, CRC, Epidemiology, Cancer, Metastasis, Bevacizumab, Disease, Woman, Population, CT, Diagnosis, Palliative care, EGFR, MRI, CEA, FOLFIRI, Patent, FOLFOX, Immunotherapy, Large intestine, Awareness, Pharmaceutical industry, Medical imaging, Eluned Parrott, Pembrolizumab

The "Metastatic Colorectal Cancer Market Insight, Epidemiology and Market Forecast - 2030" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Metastatic Colorectal Cancer Market Insight, Epidemiology and Market Forecast - 2030" report has been added to ResearchAndMarkets.com's offering.
  • The drug chapter segment of the Metastatic Colorectal Cancer (mCRC) report encloses the detailed analysis of Metastatic Colorectal Cancer (mCRC) marketed drugs and mid and late stage pipeline drugs.
  • The United States Market Outlook - This section provides the total Metastatic Colorectal Cancer (mCRC) market size and market size by therapies in the United States.
  • Japan Market Outlook - The total Metastatic Colorectal Cancer (mCRC) market size and market size by therapies in Japan are provided.

Bold Therapeutics Extends South Korea Option Agreement for BOLD-100, a First-in-Class Anti-Resistance Therapeutic

Retrieved on: 
Thursday, January 13, 2022
GRP78, Stomach, National Cancer Center, Samsung Medical Center, Reactive oxygen species, Unfolded protein response, Cancer, Douglas BTD Destroyer, CEO, ROS, UPR, DNA, Therapy, Odds, Seoul National University Hospital, DNA repair, Induced cell cycle arrest, Emphasis (typography), FOLFOX, Cell death, FDA, Pharmaceutical industry

VANCOUVER, British Columbia, Jan. 13, 2022 /PRNewswire/ --Bold Therapeutics, a clinical-stage biopharmaceutical company developing BOLD-100, is pleased to announce an extension of the option agreement with an undisclosed publicly traded South Korean biopharmaceutical company, originally executed in May 2020, for development and commercialization rights to BOLD-100 in South Korea.

Key Points: 
  • VANCOUVER, British Columbia, Jan. 13, 2022 /PRNewswire/ --Bold Therapeutics, a clinical-stage biopharmaceutical company developing BOLD-100, is pleased to announce an extension of the option agreement with an undisclosed publicly traded South Korean biopharmaceutical company, originally executed in May 2020, for development and commercialization rights to BOLD-100 in South Korea.
  • Bold Therapeutics' BOLD-100 is a first-in-class ruthenium-based small molecule therapeutic that (1) alters the unfolded protein response (UPR) through selective GRP78 inhibition; and (2) induces reactive oxygen species (ROS) which causes DNA damage and cell cycle arrest.
  • "As our partner is one of the fastest growing and most respected pharmaceutical companies in South Korea, we are honored to extend this option agreement that allows us to further leverage their substantial expertise in oncology development," said E. Russell McAllister, CEO of Bold Therapeutics.
  • For more information about Bold Therapeutics, please visit the company's website at www.bold-therapeutics.com

Gilead Exercises Options to Three Arcus Biosciences Clinical-Stage Programs and Adds Research Collaboration

Retrieved on: 
Thursday, November 18, 2021
Oncology, Health, Hospitals, Clinical Trials, Pharmaceutical, Biotechnology, Lung, Docetaxel, Key Stage 3, TKI, Biology, NYSE, Exercise, Cancer, Gilead Sciences, Physician, Risk, HIV, Private Securities Litigation Reform Act, Prostate cancer, Hart–Scott–Rodino Antitrust Improvements Act, PD-L1, Time, Achievement, Research, Adenosine, Phase II, Science, File, HIV disease progression rates, PD-1, Collaboration, Durvalumab, Large-cell lung carcinoma, Partnership, Progression-free survival, AstraZeneca, CD73, U.S. Securities and Exchange Commission, TIGIT, Twitter, PDAC, Nasdaq, Medicine, Multimedia, Colon, Growth, Patient, SEC, FOLFOX, Program, COVID-19, Sacituzumab govitecan, Bevacizumab, Pharmaceutical industry

The royalties payable by Gilead to Arcus on sales for these three programs outside of the U.S. were slightly reduced.

Key Points: 
  • The royalties payable by Gilead to Arcus on sales for these three programs outside of the U.S. were slightly reduced.
  • In May 2020, Gilead and Arcus entered into a 10-year collaboration that provided Gilead immediate rights to zimberelimab and the right to opt into all other Arcus programs arising during the collaboration term.
  • In November 2021, Gilead and Arcus amended the collaboration in connection with Gileads option exercise for three of Arcuss then-clinical stage programs.
  • Concurrent with the May 2020 collaboration agreement, Gilead and Arcus entered into a stock purchase agreement under which Gilead made a $200 million equity investment in Arcus.

Gilead Exercises Options to Three Arcus Biosciences Clinical-stage Programs and Adds Research Collaboration

Retrieved on: 
Thursday, November 18, 2021
Biotechnology, Health, Pharmaceutical, Clinical Trials, Oncology, Lung, Docetaxel, Key Stage 3, TKI, Biology, NYSE, Exercise, Cancer, Gilead Sciences, Physician, Risk, HIV, Private Securities Litigation Reform Act, Prostate cancer, Hart–Scott–Rodino Antitrust Improvements Act, PD-L1, Time, Achievement, Research, Adenosine, Phase II, Science, File, HIV disease progression rates, PD-1, Collaboration, International, Durvalumab, Large-cell lung carcinoma, Partnership, Progression-free survival, AstraZeneca, CD73, U.S. Securities and Exchange Commission, Software, TIGIT, Twitter, PDAC, Nasdaq, Medicine, Colon, Growth, Patient, SEC, FOLFOX, Program, COVID-19, Sacituzumab govitecan, Webcast, Bevacizumab, Pharmaceutical industry

The royalties payable by Gilead to Arcus on sales for these three programs outside of the U.S. were slightly reduced.

Key Points: 
  • The royalties payable by Gilead to Arcus on sales for these three programs outside of the U.S. were slightly reduced.
  • In May 2020, Gilead and Arcus entered into a 10-year collaboration that provided Gilead immediate rights to zimberelimab and the right to opt into all other Arcus programs arising during the collaboration term.
  • In November 2021, Gilead and Arcus amended the collaboration in connection with Gileads option exercise for three of Arcuss then-clinical stage programs.
  • Concurrent with the May 2020 collaboration agreement, Gilead and Arcus entered into a stock purchase agreement under which Gilead made a $200 million equity investment in Arcus.

Apexigen Announces New Phase 2 Clinical Data on CD40 Antibody Sotigalimab at the SITC 2021 Annual Meeting

Retrieved on: 
Friday, November 12, 2021
Population, Cancer, Șaeș, Chemokine, TME, B cell, Immunotherapy, Tumor microenvironment, PD-1, PDAC, Therapy, Oncology, CD8, Mechanism of action, Safety, AES, Biomarker, Neoadjuvant therapy, RT, Rectum, Cytokine, SAN, Research, Yale school, Conference, Annual general meeting, GLOBE, SD, FC, Poster, Patient, University of Texas Southwestern Medical Center, Macrophage, Radiation, Society, Nivolumab, Radiation therapy, Cytokine release syndrome, IO, Contraindication, Protein, DC, ORR, Yale School of Medicine, RECIST, FOLFOX, Melanoma, SITC, Sarcoma, Monocyte, RNA, Immune system, NK, 2021 Essex County Council election, Pancreatic cancer, Incidence, Assistant, Pharmaceutical industry, Vaccine, Medical imaging, Medical device

SAN CARLOS, Calif., Nov. 12, 2021 (GLOBE NEWSWIRE) -- Apexigen, Inc., a clinical-stage biopharmaceutical company focused on discovering and developing a new generation of antibody therapeutics for oncology, today announced new clinical data on sotigalimab in three poster presentations at the Society for Immunotherapy of Cancer’s (SITC) 36th Annual Meeting, being held both virtually and in Washington, D.C., November 10-14, 2021. Sotigalimab, Apexigen’s lead immuno-oncology (I-O) therapeutic, is a potentially first-in-class and best-in-class CD40 agonist, with unique epitope specificity and Fc receptor engagement for optimal therapeutic effect and tolerability.

Key Points: 
  • The posters will be available on-demand through the SITC conference portal starting Friday, November 12, 2021, at 7:00 a.m.
  • The abstract was selected by members of the SITC Communications Committee to be presented at the SITC 2021 Annual Meeting Press Conference, which is a virtual session showcasing selected abstracts.
  • However, after sotigalimab and RT there was an increase of each cell type and DCs were the dominant cell expressing CD40.
  • Seven product or product candidates discovered using APXiMAB are currently commercially available or in clinical development, either internally by Apexigen or by its licensees.

Celyad Oncology Presents Preclinical Data on Allogeneic CAR T Therapy Program and Highlights KEYNOTE-B79 Clinical Trial Design at the Society for Immunotherapy of Cancer (SITC) 36th Annual Meeting

Retrieved on: 
Friday, November 12, 2021
MSD, Molecule, Euronext, Safety, SITC, Cancer, Lymphatic system, Private Securities Litigation Reform Act, Intrinsic termination, Clinical trial, Method, Wallonia, Merck, RNA, Mont-Saint-Guibert, Society, Pembrolizumab, COVID-19, CAR, Western literature, SA, Annual report, Forward-looking statement, TIM, Â, Society for Immunotherapy of Cancer, Annual general meeting, Company, GLOBE, CET, Merck Sharp & Dohme Federal Credit Union, U.S. Securities and Exchange Commission, SEC, Interleukin 18, Immunotherapy, DNA, Poster, Patient, Risk, Uncertainty, Merck & Co., NKG2D, FOLFOX, Pharmaceutical industry, Vaccine

We believe our CAR T cells are the only allogeneic CAR T cells currently in human clinical trials that avoid generating double-strand DNA breaks.

Key Points: 
  • We believe our CAR T cells are the only allogeneic CAR T cells currently in human clinical trials that avoid generating double-strand DNA breaks.
  • We believe that KEYNOTE-B79 will be the first clinical trial to evaluate an allogeneic CAR T with an anti-PD-1 therapy in solid tumors.
  • We look forward to initiating the study in the coming weeks and providing clinical updates to the CYAD-101 program in 2022.
  • These data support the ongoing development of the Companys shRNA-based allogeneic, IL-18-armored CAR T candidate CYAD-203 as well as future allogeneic IL-18-armored CAR T candidates.

Celyad Oncology Announces Third Quarter 2021 Financial Results and Recent Business Highlights

Retrieved on: 
Wednesday, November 10, 2021
MSD, AML, Cancer, MSS, COVID-19, SA, University, Uncertainty, Risk, MICA, Safety, Intrinsic termination, Technology, Cyclophosphamide, Research, Forward-looking statement, TIM, Annual general meeting, GLOBE, PMMR 62, Horizon Discovery, Patient, CAR, Merck & Co., GPC3, BCMA, Lymphatic system, Private Securities Litigation Reform Act, Drug discovery, Society, Pembrolizumab, Glypican 3, LLC, U.S. Securities and Exchange Commission, SEC, Immunotherapy, NKG2D, FOLFOX, Euronext, SITC, Graft-versus-host disease, Wallonia, Merck, RNA, ASH, Mont-Saint-Guibert, TCR, MDS, MICB, Annual report, Society for Immunotherapy of Cancer, Company, Development, Interleukin 18, Investigational New Drug, Pharmaceutical industry, Vaccine, Animal, Medical device

MONT-SAINT-GUIBERT, Belgium, Nov. 10, 2021 (GLOBE NEWSWIRE) -- Celyad Oncology SA (Euronext & Nasdaq: CYAD) (the Company), a clinical-stage biotechnology company focused on the discovery and development of chimeric antigen receptor T cell (CAR T) therapies for cancer, today announced an update on its financial results and recent business developments for the fiscal quarter ended September 30, 2021.

Key Points: 
  • MONT-SAINT-GUIBERT, Belgium, Nov. 10, 2021 (GLOBE NEWSWIRE) -- Celyad Oncology SA (Euronext & Nasdaq: CYAD) (the Company), a clinical-stage biotechnology company focused on the discovery and development of chimeric antigen receptor T cell (CAR T) therapies for cancer, today announced an update on its financial results and recent business developments for the fiscal quarter ended September 30, 2021.
  • Research & Development Day held on July 20, 2021, during which the management team provided:
    Updates on the allogeneic CAR T clinical candidates CYAD-211 and CYAD-101.
  • Celyad Oncology was founded in 2007 and is based in Mont-Saint-Guibert, Belgium and New York, NY.
  • Forward-looking statements may involve known and unknown risks and uncertainties which might cause actual results, financial condition, performance or achievements of Celyad Oncology to differ materially from those expressed or implied by such forward-looking statements.